Passage Bio (Passage Bio) Change In Working Capital : $-7.06 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Passage Bio Change In Working Capital?

Passage Bio's change in working capital for the quarter that ended in Mar. 2024 was $-4.18 Mil.

Passage Bio's change in working capital for the fiscal year that ended in Dec. 2023 was $5.34 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Passage Bio Change In Working Capital Historical Data

The historical data trend for Passage Bio's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Passage Bio Change In Working Capital Chart

Passage Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-5.94

14.44

11.42

-8.49

5.34

Passage Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															8.23	2.30	-0.91	-4.29	-4.18

Passage Bio Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.06 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Passage Bio Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Passage Bio's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Passage Bio (Passage Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Passage Bio Inc (NAS:PASG) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103

Website

https://www.passagebio.com

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Executives

Kathleen Borthwick	officer: SVP, Interim CFO	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Simona King	officer: Chief Financial Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Dolan Sondhi	director	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alexandros Fotopoulos	officer: Chief Technical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Sandip Kapadia	director	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
William Chou	director, officer: Chief Executive Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Monika Maria Toernsen	officer: Chief Commercial Officer	ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Michael E. Kamarck	director	C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Mark S Forman	officer: Chief Medical Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Bruce A Goldsmith	director, officer: CEO and President	C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brian Burkavage	officer: Controller	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341